(Q45872598)

17 December 2017

title

Risk of inhibitor development in mild haemophilia A increases with age. (English)

1 reference

17 December 2017

0 references

0 references

5

1 reference

17 December 2017

author name string

E P Mauser-Bunschoten

1

1 reference

17 December 2017

I E M Den Uijl

2

1 reference

17 December 2017

R E G Schutgens

3

1 reference

17 December 2017

G Roosendaal

4

1 reference

17 December 2017

publication date

19 August 2011

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

18

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

263-267

1 reference

17 December 2017

Molecular mechanisms of mild and moderate hemophilia A.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

What factors influence the age at diagnosis of hemophilia? Results of the French hemophilia cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Genetic risk factors for inhibitors to factors VIII and IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02629.X

10.1111/J.1365-2516.2011.02629.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017